No Data
Active and newly listed stocks during the morning session.
*Raccoon HD <3031> 782 +66 announced the implementation of a high-level share buyback program, leading to expectations of supply and demand. *Aeon Fantasy <4343> 2395 +170 Short covering predominant due to the movements in the earnings revision. *USC <4732> 1279 +27 Speculative buying also seen in response to the news of an on-site inspection by IDOM. *Mitsubishi Motors <7211> 408.6 +4.7 Clues include progress in yen depreciation and other factors. *Epson <6724> 2820.5 +29
Insider decrases its stake in Carna Biosciences(4572.JP) to 3.33%
On Oct 21, モルガン・スタンレー・アンド・カンパニー・インターナショナル・ピーエルシー and related parties submitted the Change Report to Ministry of Finance. The report shows that モルガン・スタンレー・アンド・カンパニー・インターナショナル・ピーエルシー and
Insider holds 7.33% of shares in Carna Biosciences(4572.JP)
On Oct 21, Athos Capital Limited submitted the Large Shareholding Report to Ministry of Finance to disclose its 7.33% ownership of the shares in $Carna Biosciences(4572.JP)$. Source: Edinet
Insider holds 5.53% of shares in Carna Biosciences(4572.JP)
On Oct 4, モルガン・スタンレー・アンド・カンパニー・インターナショナル・ピーエルシー submitted the Large Shareholding Report to Ministry of Finance to disclose its 5.53% ownership of the shares in $Carna Biosciences(4572.JP)$.
Despite softness and the rise in long-term US interest rates, the lower levels appear to be holding firm.
[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to have a soft opening. In the US stock market on the 25th yesterday, the Dow Jones fell by 293.47 points (-0.70%) to 41,914.75, marking a decline for the first time in 5 days. The Dow Jones had been setting record highs consecutively until the previous day, leading to profit-taking selling, and the decline in August new home sales from July added to the pressure on stock prices. The Nasdaq was weighed down by the rise in long-term interest rates, but the semiconductor sector remained strong, providing support at lower levels and closing trading with a slight gain.
Noil Immun, Carna Bio, and others.
Collaborative relationship company stock sale profit of 6.4 billion yen expected to be recorded as special profit for <3908> Capital increase through third-party allotment by Carnabyo (1,056,00 shares) for <4572> Approximately 1.4 billion yen in subsidy income from Saifyuz to be recorded as non-operating income for <4892> Takara Bio <4974> and business alliance in the development of Noil Immun NIB103 <4893> <7776> Seaseed's clinical trial start date for homologous chondrocyte sheet (CLS2901C) is expected to be delayed.
No Data
No Data